[3H]6-keto-PGF1< was recovered from the supernates of the combined cell suspensions after stimulation by all three agents. The order of PGI2 production initiated by the stimuli was ionophore > thrombin > collagen. The amounts of platelet [3H]TXB2 recovered were markedly reduced by the addition of aspirin-treated endothelial cells. In separate experiments, 6-keto-PGFi,c, and TXB2 were quantitated by radioimmunoassay; the results paralleled those obtained with the use of radiolabeling. The quantity of 6-keto-PGF1,, measured by radioimmunoassay represented amounts of PGI2 sufficient to inhibit platelet aggregation. These results were obtained when
A B S T R A C T
Received for publication 11 February 1980 and in revised form 27 June 1980. < 200,000 platelets/Al were combined with 3,000-6,000 aspirin-treated endothelial cells/,ul. At higher platelet levels the proportion of 6-keto-PGF,l, to TXB2 decreased and platelet aggregation occurred. Control studies indicated that aspirin-treated endothelial cells could not synthesize PGI2 from exogenous radioactive or endogenous arachidonate when stimulated with thrombin. Therefore the endothelial cell suspensions could only have used endoperoxides from stimulated platelets.
Thus, under our experimental conditions, production by endothelial cells of PGI2 from endoperoxides derived from activated platelets could be demonstrated by two independent methods. These experimental conditions included: (a) enhanced platelet-endothelial cell proximity, as attainable in stirred cell suspensions; (b) use of increased endothelial cell/platelet ratios; and (c) utilization of arachidonate of high specific activity in radiolabeling experiments. Furthermore, when a mixture of platelets and endothelial cells that were not treated with aspirin was stimulated with thrombin, more than twice as much 6-keto-PGF,10 was formed than when endothelial cells were stimulated alone. These results indicate that endothelial cells can utilize platelet endoperoxides for PGI2 formation to a significant extent.
INTRODUCTION
Prostacyclin (PGI2)' (1) and thromboxane A2 (TXA2) (2) are the main products of the cyclooxygenase pathways in endothelial cells and platelets, respectively. PGI2 is a strong vasodilator and inhibitor of platelet aggregation. TXA2 is a powerful vasoconstrictor and a stimulator ofplatelet aggregation. PGI2 and TXA2 are enzymati-cally derived from a common precursor, the unstable prostaglandin endoperoxide PGH2. Bunting and associates (3, 4) had suggested that a biochemical interaction took place between platelets and vessel walls in which endoperoxides from stimulated platelets were also used by the vessels to form PGI2. In this manner a balance might be maintained between the proaggregatory effect of TXA2 and the antiaggregatory action of PGI2 (see reference 5 for review).
We previously demonstrated that exogenously added radioactive PGH2 was converted to PGI2 by endothelial cell monolayers (6) . In the present study we show that stimulated [3H]arachidonate-labeled platelets can serve as a source of endoperoxide for PGI2 synthesis by endothelial cells. This was demonstrated with the use of [3H]arachidonate-labeled platelets and radio thin-layer chromatography (TLC), as well as with unlabeled platelets and radioimmunoassay.
METHODS
Platelet collection and processing. Platelet-rich plasma (PRP) was prepared in a plastic pack system as previously described (7) . Samples of PRP were removed for evaluation of the burst of 02 consumption after stimulation with collagen (7) . The latter was used as a criterion for activity of platelet cyclooxygenase.
An average of 80 ml PRP (calculated by weight) containing -37-50 x 109 platelets was expressed into a satellite bag. 1 mCi (5 ,ug) [3H]arachidonate (20:4) , 61.0 Ci/mmol sp act (New England Nuclear, Boston, Mass.), was initially converted to the sodium salt with 0.2 ml 0.01 M Na2CO3 (6) and added to PRP in 3 ml Tris-saline-glucose (TSG) buffer (8) containing 1% albumin. The satellite bag was enclosed in a second plastic bag and incubated in a shaking water bath at 20 oscillations/ min for 1 h at 37°C (8) .
After incubation, the labeled PRP was processed as previously described (7) . The once-washed platelets were finally suspended in 0.15 M saline and maintained at 4°C. Radioactivity and platelet count (microhematocrit technique) (9) were then determined. The above procedure yielded an average of 38 x 109 platelets containing -600,000-800,000 cpm/10S platelets.
Experiments with endothelial cell monolayers. Human endothelial cells derived from umbilical cords were cultured and acetylsalicylic acid (ASA)-treated as previously described (6, 10 (11) . The extracts were dried and taken to a volume of 0.1 ml with chloroform:methanol (2:1) and aliquots removed for scintillation counting (1) . TLC (double development), scanning, and quantitation techniques have been described previously (1, 6) .
Control experiments were carried out to ascertain whether 6,15-diketo PGF,,, was being formed in addition to 6-ketoprostaglandin F1,0 (6-keto-PGF1,) (Wong et al. [12] demonstrated by formation of 6-keto-PGFI, (62% yield) fol-lowing addition of ['4C]PGH2 to the cell suspensions as previously described (6).
Radioimmunoassays for 6-keto-PGFi, and TXB2. A radioimmunoassay for 6-keto-PGF,1 was developed in our laboratory using antisera raised in rabbits against synthetic 6-keto-PGF,i,, conjugated to keyhole limpet hemocyanin.2 PGI2 in the supernates of cell suspensions was converted to 6-keto-PGF1,, by acidification to pH 3 with 1 N HC1 and subsequent neutralization, or by incubation for 1 h at 37°C. Radioimmunoassay was performed by incubating 100 plI of diluted test sample (in 50 mM Hepes buffer, pH 7.5, containing 0.2% bovine serum albumin), 100 Ald ofantiserum at a dilution of 1 to 3,200, and 100 ul of [3H]6-keto-PGF,l (10,000 dpm, 100 Ci/ mmol, sp act, New England Nuclear). Following incubation at 20°C for 18 h, the bound radioactivity was separated from residual-free radioactivity by adding 100 l.a ofa 1% suspension of protein A-containing Staphylococcus aureus (Pansorbin, Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.), incubating for 1 h at 20°C, and centrifuging. Aliquots of the supemate were then counted in a liquid scintillation counter. Standard curves with 6-keto-PGF10 were run with each assay and were superimposable with standard curves using PGI2. Half displacement of labeled [3H]6-keto-PGF,1, was achieved at 60 pg/sample. This assay had low crossreactivities with other prostaglandins similar to other assays previously reported.
The radioimmunoassay for TXB2 was similarly developed in our laboratory using antiplasmas raised in rabbits against TXB2 conjugated to keyhole limpet hemocyanin. Conditions for the assay were similar to those used in the assay described above, except that the antiplasma was used at a dilution of 1 lysis. In no instance did the presence of a platelet lysate increase 6-keto-PGF,l formation as measured by radioimmunoassay. For example, the quantity of 6-keto-PGF1,, produced by ASA-treated endothelial cells in the presence of a platelet suspension containing 40% platelet lysate following thrombin stimulation, was 5.5 ng/0.5 ml incubation mixture. In the presence of a normal platelet suspension these endothelial cells produced 8.4 ng 6-keto-PGF,JO.5 ml. In an additional experiment 40% platelet lysate was added to the usual platelet number to compensate for platelet dilution by the lysate. In this instance 6.4 ng of 6-keto-PGF,0 was measured per 0.5 ml compared with the 8.4 ng/0.5 ml in the control containing no lysate. Stimulus-associated lysis was studied at two concentrations of ionophore, 1 and 0.3 uMM. The higher concentration of ionophore induced a 12-fold increase in 6-2 Levin, R., E. A. Jaffe, B. B. Weksler, and K. Tack-Goldman. Manuscript in preparation.
keto-PGF,1 production, but only a 1.8-fold increase in lactic dehydrogenase release. Thus, PGI2 production could not be correlated with the degree of platelet lysis induced by this stimulus. An additional control experiment to evaluate possible endothelial cell recovery from ASA treatment was performed. When ASA-treated radiolabeled platelets were stimulated with thrombin in the presence of ASA-inhibited endothelial cell suspensions, radioactive arachidonic acid was released from the platelets (data not shown). However, no 6-keto-PGF1,, was formed by the endothelial cells. This is further evidence that the ASA-inhibited endothelial cells could not metabolize arachidonic acid to PGI2 during the experimental procedure.
RESULTS
Stimulated platelets as a source of endoperoxide for PGI2 synthesis. Combined suspensions of radiolabeled platelets (200,000/1l) and ASA-treated endothelial cells (3,000-6,000/I) were stimulated with either ionophore, thrombin or collagen, in aggregometer cuvettes, and the response was recorded. In radiolabeling experiments cuvette contents were then processed for lipid analysis as described in Methods. When nonlabeled platelets were studied, supernates were processed for radioimmunoassay of 6-keto-PGFIc,, and TXB2. Thus, the platelet aggregation response and formation of PGI2 and TXA2 were evaluated in the same sample. In the absence of endothelial cells, 6-ketoPGFj, was not detected. Furthermore (Fig. lb) , whereas platelets alone responded normally (Fig. la) . The TLC radioscan (Fig. 2) (Table II) . In the absence of ASA-treated endothelial cells (Fig. la) , ionophore-treated platelets produced 1.9 times more TXB2 (24,940 cpm) than in their presence (12,997 cpm let aggregation responses to thrombin were always markedly reduced in the presence ofASA-treated endothelial cell suspensions (Fig. 3) , and production of 6-keto-PGF1,, was demonstrable. Table II . Total volume of test mixture was 0.5 ml.
tively, after thrombin addition. As noted with ionophore, inhibition of thrombin-induced platelet aggregation (Fig. 3b) occurred, even in the presence of thromboxane production (Table II) . Thrombin-treated platelets generated 1.4 times more thromboxane (9,555 cpm) in the absence of ASA-treated endothelial cells than in their presence (6,624 cpm). When measured by radioimmunoassay in a separate experiment the quantities were 16.3 ng and 7.6 ng, respectively. When both platelets and endothelial cells were pretreated with ASA and then stimulated with thrombin, no 6-keto-PGF1I was measurable.
Collagen. In the presence of ASA-treated endothelial cells inhibition of aggregation responses to collagen was comparable to that observed with thrombin (Fig. 4) . However, smaller quantities of 6-keto-PGFI and TXB2 were detected following collagen stimulation than in the case of thrombin or ionophore (Table II) . By radioimmunoassay collagen stimulation of the platelet-endothelial cell mixtures resulted in production of 0.1 ng 6-keto-PGF,, and 2.5 ng TXB2. As can be seen in Table II and from the radioimmunoassay results, the quantitative profile of endothelial cell PGI2 production was ionophore > thrombin > collagen, and the pattern of thromboxane production by platelets in the combined suspensions followed the same order. In the absence of ASA-treated endothelial cells the quantity of platelet thromboxane recovered in the supernate following collagen stimulation was 5.1 times higher (5, 128 cpm) than in their presence (1, 008 cpm). When measured by radioimmunoassay in a separate experiment the quantities were 9.9 and 2.5 ng, respectively.
Evaluation of the platelet contribution to PGI2 formation by endothelial cells. This with thrombin, 19 .2 ng of 6-keto-PGF,1 were formed (i.e., a 2.5-fold increase). Endothelial cells from this batch were treated with ASA and added to platelets, which were then the sole source of endoperoxide. Subsequent stimulation with thrombin yielded 8.4 ng 6-keto-PGF1,0, which was derived from platelet endoperoxides. This was similar to the quantity produced by non-ASA-treated endothelial cells alone (7.7 ng) . Thus, in this system approximately half of the total 6-keto-PGF,, produced by endothelial cell-platelet mixtures was derived from platelet endoperoxides.
Relation of platelet concentration to PGI2 production by ASA-treated endothelial cells. Experiments were carried out wherein 1.45 x 106 endothelial cells (2,900/,41) were combined with either 1 x 108 or 15.5 x 108 platelets (2 or 31 x 105/,u) and then stimulated with ionophore, thrombin, or collagen. The increase in platelet concentration resulted in formation of greater amounts of both 6-keto-PGFi,u and TXB2 (Table III) . However, the production of TXB2 was increased much more than that of 6-keto-PGFiu, as shown by the four-to sevenfold increase in the ratio TXB2/6-keto-PGF1,, (Table III) . In another experiment the effect of platelet concentration on the aggregation response was examined. Combining 200,000 platelets/ pu with 3,850 ASA-treated endothelial cells/,u1, followed by stimulation with thrombin (5 U/ml), resulted in inhibition ofaggregation comparable to that depicted in Fig. 3b . However, when the platelet concentration was raised to 500,000/4ul the inhibitory effect of ASAtreated endothelial cells was lost and a normal aggregation response comparable with that in Fig. 3a ensued.
Studies with ASA-treated endothelial cell monolayers and suspensions. lonophore stimulation of radiolabeled platelets added to ASA-treated endo- * lonophore (1 ,uM) , thrombin (10 U/ml), collagen (30 ,ug/ml), Ca++ (3 mM). Total volume was 0.5 ml.
Includes a small quantity of PGE2 that overlapped with TXB2 on these TLC plates. thelial cell monolayers resulted in less PGI2 production than that observed in the same experiment with platelets and ASA-endothelial cell suspensions (491 vs. 782 cpm). A similar effect was noted when thrombin was the stimulus. Monolayer experiments carried out in the presence of the thromboxane synthetase inhibitors imidazole and U54701 resulted in an increase in PGI2 production as reported by others (14) (15) (16) . In the case of ionophore stimulation, counts in the 6-keto-PGF1,, TLC peak increased from 491 to 3,826 epm with imidazole, and to 4,177 cpm with U54701. The effect of imidazole and U54701 was also apparent when platelets and ASA-treated endothelial cell suspensions were used. With ionophore, the counts in the 6-keto-PGF10 area rose from 782 to 12,030 cpm in the presence of imidazole, and to 10,847 cpm with U54701. Results with thrombin in the presence of TXA2 synthetase inhibitors were comparable to those with ionophore in that PGI2 production increased 10-fold in the ASAtreated endothelial cell monolayers and 14-fold in the suspensions.
DISCUSSION
Although endothelial cells can synthesize PGI2 from endogenous precursors (17) (18) (19) or from exogenously provided endoperoxides (6) or arachidonate (1, 6, 16) , PGI2 synthesis by endothelial cells from platelet-derived endoperoxides has been demonstrated only in the presence of thromboxane synthetase inhibitors (14) (15) (16) . These results indicated to us that utilization of platelet endoperoxides for PGI2 synthesis by ASAtreated endothelial cells might be possible even in the absence of thromboxane synthetase inhibitors.
We used two independent methods for detection of 6-keto-PGF1,0, radiolabeling and radioimmunoassay.
The radiometric experiments made it possible to follow the metabolism of platelet-derived endoperoxides by ASA-treated endothelial cells. The radioimmunoassay provided quantitative information on the total amount of6-keto-PGF1,, generated. As previously reported (18) , addition of 50 pg PGI2 to 0.5 ml PRP inhibited aggregation induced by 0.3 mM sodium arachidonate. In addition, the radioimmunoassays allowed us to compare the quantity of 6-keto-PGF1,, generated endogenously by the endothelial cells alone with that derived from platelet endoperoxides. The high specific activity of [3H]arachidonate for radiolabeling permitted studies of platelets in the range of 200,000/,ul and increased the sensitivity of the TLC detection system. Use of suspensions of endothelial cells in preference to monolayers enhanced platelet-endothelial cell proximity by concentrating the components in a small volume and permitted adequate mixing. Under these conditions both aggregometry and analysis of products could be performed on the same sample.
When low endothelial cell-to-platelet ratios (-1:1,000) were used, production of 6-keto-PGF1,0 relative to TXB2 was low and the platelets aggregated upon stimulation. The ratio of endothelial cells to platelets was then increased to -1:50 in order to approach that which occurs in vivo. The surface area of an endothelial cell is -30 x 50 pm (1,500 gm2) (10) and the area of the capillary vasculature in a 70-kg man is --1,000 m2 (20) . Thus the capillary vasculature of the average subject is lined by -7 x 1011 endothelial cells. Assuming a blood volume of 5,000 ml and a platelet count of -300,000/,u, the vasculature would contain 1.5 x 1012 platelets. Therefore in vivo the ratio of endothelial cells to platelets, at least in capillaries, approaches 1:1. At our endothelial cell to platelet ratio of 1:50, PGI2 was produced and platelet aggregation was inhibited. PGI2 synthesis from platelet endoperoxides. lonophore is a strong inducer of platelet aggregation and TXA2 production as well as of endothelial cell PGI2 synthesis (18) . In the experiments reported here ionophore was the most potent stimulus of PGI2 production. Inhibition of platelet aggregation in mixtures of ASAtreated endothelial cells and platelets was also the most pronounced with ionophore (Fig. 1) . While thrombin was a stronger stimulus for both PGI2 and TXA2 production than was collagen, the inhibitory effects of ASA-treated endothelial cells on thrombin-and collagen-induced aggregation were similar (Figs. 3 and 4) .
When a mixture of platelets and endothelial cells was stimulated by thrombin in an ASA-free system, approximately twice as much 6-keto-PGF10 as measured by radioimmunoassay formed than when platelets were omitted. A further experiment indicated that the increase in 6-keto-PGF,,1 noted in the presence of platelets was due to transfer of platelet endoperoxides to the endothelial cells. Endothelial cells stimulated bv thrombin to produce PGI2 from endogenous sources in the absence of ASA produced no more PGI2 than when ASA-treated endothelial cells were combined with platelets as the sole source of endoperoxides. Thus, in our system endothelial cells formed approximately half of their PGI2 from platelet-derived endoperoxides.
In our experiments stimulated platelets synthesized less thromboxane when admixed with ASA-treated endothelial cells than when present in the incubation system alone. A possible explanation is that some ofthe available platelet endoperoxides were diverted to PGI2 synthesis when ASA-treated endothelial cells were present with the platelets. An additional possibility is that the PGI2 formed by the ASA-treated endothelial cells led to inhibition of platelet aggregation and therefore to a decrease in further TXA2 production.
Inhibition of TXA2 synthesis with imidazole or U54701 presumably resulted in accumulation of endoperoxides (14-16), thereby facilitating PGI2 synthesis by ASA-treated endothelial cells in both monolayers and suspensions. In the presence of TXA2 synthetase inhibitors, ASA-treated endothelial cells generated PGI2 from endoperoxides formed in thrombin-treated platelets, even when albumin was included in the medium. However, in the presence of albumin the quantities of PGI2 formed were lower than in its absence, and there was an increase in PGD2 formation. The latter observations are in agreement with the reported enhanced isomerization of endoperoxides in albumin (15, 21) . Thus, in order to maximize the sensitivity of the assay systems, albumin was not included in the incubation medium in the remainder of the experiments.
There therefore appear to be two mechanisms for PGI2 synthesis by cultured human endothelial cells. The first involves synthesis of PGI2, from endogenous precursors, and the second occurs from endoperoxides derived from stimulated platelets. Specific conditions under which one or both mechanisms may be operative have not as yet been established.
